Luis Ruilope

Unidad de Hipertensión, Hospital 12 de Octubre, Spain

Luis Ruilope is Associate Professor of Internal Medicine at Complutense University, Madrid, and Head of the Hypertension Unit at 12 de Octubre Hospital, Madrid. His research focuses on hypertension and the kidney.

He is International Fellow of the Council for High Blood Pressure Research and of the Council of the Kidney in CV disease of the AHA and Actual President of the Spanish Hypertension Society. He is Member of the Editorial Boards of Journal of Hypertension, Blood Pressure, Medicina Clínica, Hypertension, Journal of Human Hypertension, Journal American Society of Nephrology and Nephrology, Dialysis & Transplantation. He is also Associate Editor of Current Hypertension Report and Member of the Steering Committee of the following Studies HOT, INSIGHT, SCOPE, CONVINCE, ROADMAP, ASCEND, and European coordinator of the study IDNT.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Cardiovascular Disorders > Hypertension (since 15 November 2005)

All recent recommendations

• 12.4
  Dabigatran versus warfarin in patients with atrial fibrillation.
  Recommended by Robert Ruff, Brian Olshansky with Rakesh Gopinathannair, Luis Ruilope with José A García Donaire, Wilbert Aronow, Fred Weaver with Sung Ham, Philip Gorelick with Fernando Testai, I Eli Ovsyshcher with Guy Amit, Chim Lang with Anna Maria Choy, Heather Bloom, Harri Jenkins, Wolfgang Schoels, Ashfaq Shuaib, Carlos Kase with Aleksandra Pikula , Megan Leary with Angela Adams, Jeffrey Veluz
  
• 4.8
  Valsartan for prevention of recurrent atrial fibrillation.
  Recommended by Luis Ruilope with José Antonio García-Donaire, Wilbert Aronow
  
• 6.0
  Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
  Recommended by Luis Ruilope with Jose A Garcia-Donaire
  
• 3.0
  Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
  Recommended by Luis Ruilope with José Antonio García-Donaire
  
• 8.4
  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
  Recommended by William Mitch, Enyu Imai, Luis Ruilope with José A García Donaire, Neil Turner with Neeraj Dhaun
  
• 3.0
  Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis.
  Recommended by Luis Ruilope with Jose Antonio García Donaire
  
• 4.8
  Prognostic significance of between-arm blood pressure differences.
  Recommended by Ehud Grossman, Luis Ruilope with Jose Antonio García-Donaire
  
• 6.0
  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
  Recommended by Luis Ruilope
  
• 6.0
  International Diabetes Federation: a consensus on Type 2 diabetes prevention.
  Recommended by Luis Ruilope
  
• 3.0
  A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
  Recommended by Luis Ruilope